Drugs / AVT29
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07489131 | Apr 2026 → Jul 2027 expected | diabetic macular edema | Alvotech Swiss AG | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVT29 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07489131 ↗ |
| Known as | aflibercept HD | “AVT29 (proposed aflibercept HD biosimilar)” NCT07489131 ↗ |
| Route | Intravitreal | “Patients will receive IVT injections of AVT29” NCT07489131 ↗ |